Company Overview and News


Add BDX
to your dashboard

Headline News

EU mergers and takeovers (Oct 18)

2017-10-18 reuters
BRUSSELS, Oct 18 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (49-0)

Becton Dickinson wins conditional EU approval for $24 bln Bard buy

2017-10-18 reuters
BRUSSELS (Reuters) - U.S. medical equipment supplier Becton Dickinson (BDX.N) secured EU antitrust approval for its $24-billion acquisition of U.S. peer C R Bard (BCR.N) after it agreed to sell two businesses to allay competition concerns. (33-0)

Becton Dickinson & Co (BDX) a Buy on Robust Quant Score

2017-10-17 investorplace
Portfolio Grader currently ranks Becton Dickinson & Co (NYSE:BDX) a Buy. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier researches and ranks nearly 5,000 stocks each week. This represents no change from the previous week and is the same ranking BDX has had from Portfolio Grader for 5 months. (33-0)

EU mergers and takeovers (Oct 17)

2017-10-17 reuters
BRUSSELS, Oct 17 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (57-0)

EU mergers and takeovers (Oct 16)

2017-10-16 reuters
BRUSSELS, Oct 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (57-0)

EU mergers and takeovers (Oct 13)

2017-10-13 reuters
BRUSSELS, Oct 13 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (81-0)

The Lower Volatility Stock Portfolio For Retirees And Others

2017-10-12 seekingalpha
I recently had a look at SPDR sectors through the last two major market corrections in search of lower volatility or drawdown. (333-1)

EU mergers and takeovers (Oct 12)

2017-10-12 reuters
BRUSSELS, Oct 12 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (81-0)

Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022

2017-10-12 prnewswire
The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022. (33-0)

Cancer Biomarkers Market Research Report 2017-2022

2017-10-11 prnewswire
The "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to Research and Markets' offering. (33-0)

Cancer Biomarkers Market 12.2% CAGR to 2022 Led by North America

2017-10-11 prnewswire
The global cancer biomarkers market is forecast to reach $20.48 billion by 2022 from $11.53 billion in 2017 at a CAGR of 12.2% during (2017-2022) driven by the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies according to ReportsnReports. (45-0)

Molecular Diagnostics: Technologies and Global Markets

2017-10-10 prnewswire
NEW YORK, Oct. 10, 2017 /PRNewswire/ -- The global molecular diagnostics market was valued at nearly $10.6 billion in 2016. The market is projected to grow at a compound annual growth rate (CAGR) of 14.3% from 2017 through 2022 to reach $12.2 billion by 2017 and $23.8 billion by 2022. Read the full report: https://www.reportlinker.com/p01140654 • Microarrays as a segment should reach $5.2 billion by 2017 and nearly $13. (35-0)

Meridian Bioscience Appoints as Chief Executive Officer

2017-10-10 devicespace
CINCINNATI, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has appointed John (Jack) P. Kenny as Chief Executive Officer, effective October 9, 2017. This addition to Meridian’s management team is consistent with the succession planning described in our May 10, 2017 press release. Mr. Kenny joins Meridian after a search of several months by a Special Committee of the Board of Directors, working closely with management. (50-0)

Buy Rating on Becton Dickinson & Co (BDX) Shares Kept

2017-10-10 investorplace
Portfolio Grader currently ranks Becton Dickinson & Co (NYSE:BDX) a Buy. The approach to investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for 4 months. (33-0)

Price T Rowe Associates Inc /md/ - Current Holdings - Fintel.io

2017-10-10 fintel.io
Price T Rowe Associates Inc /md/ has disclosed 2,546 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 503,582,332,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Price T Rowe Associates Inc /md/'s top holdings are Amazon.com, Inc. (NASDAQ:AMZN) , Microsoft Corp. (NASDAQ:MSFT) , Apple, Inc. (NASDAQ:AAPL) , Facebook, Inc. (775-0)

EU mergers and takeovers (Oct 10)

2017-10-10 reuters
BRUSSELS, Oct 10 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (113-0)

Van Eck Associates Corp - Current Holdings - Fintel.io

2017-10-10 fintel.io
Van Eck Associates Corp has disclosed 731 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 18,291,096,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Van Eck Associates Corp's top holdings are Newmont Mining Corp. (NYSE:NEM) , Barrick Gold Corp. (NYSE:ABX) , Agnico Eagle Mines Limited (NYSE:AEM) , Franco-Nevada Corp. (102-1)

EU mergers and takeovers (Oct 9)

2017-10-09 reuters
BRUSSELS, Oct 9 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (114-0)

Technical Reports on Medical Supplies Equities -- Baxter, Antares Pharma, Integra LifeSciences, and Becton, Dickinson

2017-10-06 prnewswire
If you want a Stock Review on BAX, ATRS, IART, or BDX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Research coverage has been initiated by DailyStockTracker.com on Baxter International Inc. (NYSE: BAX), Antares Pharma Inc. (NASDAQ: ATRS), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and Becton, Dickinson and Co. (NYSE: BDX). These companies are part of the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. (368-1)

BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call

2017-10-05 prnewswire
FRANKLIN LAKES, N.J., Oct. 5, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2017 earnings conference call on Thursday, November 2, 2017, at 8:00 a.m. (ET).  BD will issue a press release detailing the quarter's earnings earlier that morning. (33-0)

Cancer Biomarkers Market Worth 20.48 Billion USD by 2022

2017-10-05 prnewswire
According to a new market research "Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022", Published by MarketsandMarkets™, the market is projected to reach USD 20.48 Billion by 2022 from USD 11.53 Billion in 2017, at a CAGR of 12. (33-0)

Edwards Lifesciences Is A Buy - Cramer's Lightning Round (10/3/17)

2017-10-04 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, October 3. (118-1)

Has Medtronic's Decline Made It A Buy?

2017-10-03 seekingalpha
International growth opportunities as well as acquisitions should be able to continue driving improved results for the company. (173-1)

How Boston Scientific Plans to Expand in High-Growth Markets

2017-09-29 marketrealist
Boston Scientific has registered tremendous growth recently, driven by its robust growth strategies. The company’s key growth strategies include driving category leadership and expansion around the globe, creating shareholder value through a disciplined capital allocation strategy, developing stronger capabilities, improving operating margins, and expanding across high-growth markets. (67-0)

Timothy M. Ring and David F. Melcher to Join BD Board of Directors

2017-09-29 prnewswire
FRANKLIN LAKES, N.J., Sept. 29, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that two current directors of C.R. Bard, Inc. will join the BD board of directors following the completion of BD's pending acquisition of Bard. (101-0)

CUSIP: 075887109